eicosapentaenoic acid ethyl ester has been researched along with Metabolic Syndrome in 3 studies
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this analysis was to examine the effects of icosapent ethyl (eicosapentaenoic acid ethyl ester, IPE) on high-sensitivity C-reactive protein (hsCRP) and lipid parameters in patients with metabolic syndrome, with and without stable statin therapy." | 9.20 | Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. ( Ballantyne, CM; Bays, HE; Braeckman, RA; Doyle, RT; Juliano, RA; Philip, S; Soni, PN; Stirtan, WG, 2015) |
| "Metabolic syndrome is implicated in the decline of cognitive ability." | 5.39 | Prescription n-3 fatty acids, but not eicosapentaenoic acid alone, improve reference memory-related learning ability by increasing brain-derived neurotrophic factor levels in SHR.Cg-Lepr(cp)/NDmcr rats, a metabolic syndrome model. ( Hashimoto, M; Hossain, S; Inoue, T; Katakura, M; Shido, O; Tanabe, Y; Tsuchikura, S, 2013) |
| "The aim of this analysis was to examine the effects of icosapent ethyl (eicosapentaenoic acid ethyl ester, IPE) on high-sensitivity C-reactive protein (hsCRP) and lipid parameters in patients with metabolic syndrome, with and without stable statin therapy." | 5.20 | Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. ( Ballantyne, CM; Bays, HE; Braeckman, RA; Doyle, RT; Juliano, RA; Philip, S; Soni, PN; Stirtan, WG, 2015) |
| "Metabolic syndrome is implicated in the decline of cognitive ability." | 1.39 | Prescription n-3 fatty acids, but not eicosapentaenoic acid alone, improve reference memory-related learning ability by increasing brain-derived neurotrophic factor levels in SHR.Cg-Lepr(cp)/NDmcr rats, a metabolic syndrome model. ( Hashimoto, M; Hossain, S; Inoue, T; Katakura, M; Shido, O; Tanabe, Y; Tsuchikura, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Szczuko, M | 1 |
| Kaczkan, M | 1 |
| Drozd, A | 1 |
| Maciejewska, D | 1 |
| Palma, J | 1 |
| Owczarzak, A | 1 |
| Marczuk, N | 1 |
| Rutkowski, P | 1 |
| Małgorzewicz, S | 1 |
| Hashimoto, M | 1 |
| Inoue, T | 1 |
| Katakura, M | 1 |
| Tanabe, Y | 1 |
| Hossain, S | 1 |
| Tsuchikura, S | 1 |
| Shido, O | 1 |
| Bays, HE | 1 |
| Ballantyne, CM | 1 |
| Braeckman, RA | 1 |
| Stirtan, WG | 1 |
| Doyle, RT | 1 |
| Philip, S | 1 |
| Soni, PN | 1 |
| Juliano, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels ≥ 500 mg/dL and ≤ 2000 mg/dL[NCT01047683] | Phase 3 | 229 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy[NCT01047501] | Phase 3 | 702 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Median in percent change from baseline to Week 12 in serum Apolipoprotein B levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.1 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -3.8 |
| Placebo | 4.3 |
Median percent change from baseline to Week 12 in serum Lipoprotein-associated Phospholipase A2 levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -5.1 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -17.1 |
| Placebo | -2.4 |
Median percent change from baseline to Week 12 in serum low density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -2.5 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -4.5 |
| Placebo | -3.0 |
Median percent change from baseline to Week 12 in serum non-high density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 0.0 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -7.7 |
| Placebo | 7.8 |
Median percent change from baseline to Week 12 in fasting serum triglyceride levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -7.0 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -26.6 |
| Placebo | 9.7 |
Median percent change from baseline to Week 12 in serum very low-density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 0.0 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -19.5 |
| Placebo | 13.7 |
Median percent change from baseline to Week 12 in serum Apolipoprotein B levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 1.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -2.2 |
| Placebo | 7.1 |
Median percent change from baseline to Week 12 in serum Lipoprotein-associated Phospholipase A2 levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -1.8 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -12.8 |
| Placebo | 6.7 |
Median percent change from baseline to Week 12 in serum low density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.4 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | 1.5 |
| Placebo | 8.8 |
Median percent change from baseline to Week 12 in serum non-high density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.4 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -5.0 |
| Placebo | 9.8 |
Median percent change from baseline to Week 12 in fasting serum triglyceride levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -5.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -17.5 |
| Placebo | 5.9 |
Median percent change from baseline to Week 12 in serum very low-density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 1.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -12.1 |
| Placebo | 15.0 |
1 trial available for eicosapentaenoic acid ethyl ester and Metabolic Syndrome
| Article | Year |
|---|---|
Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.
Topics: Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combina | 2015 |
Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.
Topics: Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combina | 2015 |
Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.
Topics: Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combina | 2015 |
Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.
Topics: Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combina | 2015 |
2 other studies available for eicosapentaenoic acid ethyl ester and Metabolic Syndrome
| Article | Year |
|---|---|
Comparison of Fatty Acid Profiles in a Group of Female Patients with Chronic Kidney Diseases (CKD) and Metabolic Syndrome (MetS)⁻Similar Trends of Changes, Different Pathophysiology.
Topics: Arachidonic Acid; Chromatography, Gas; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fa | 2019 |
Prescription n-3 fatty acids, but not eicosapentaenoic acid alone, improve reference memory-related learning ability by increasing brain-derived neurotrophic factor levels in SHR.Cg-Lepr(cp)/NDmcr rats, a metabolic syndrome model.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Docosahexaenoic Acids; Drug Combination | 2013 |